Search

A small number of cancer cells with the ability to change their identities and behaviors appear to be a key driver of cancer progression and its ability to evolve resistance to treatment, MSK researchers have found in a laboratory study of lung cancer.

… Wednesday, January 21, 2026 A small number of cancer cells with the ability to change their identities and behaviors appear to be a key driver of cancer progression and its ability to evolve resistance to treatment. Targeting this subpopulation of “highly plastic” cells may make current treatments more

Learn about MSK research showing that bacteria inside head and neck tumors can make a difference in their response to immunotherapy.

… Friday, January 2, 2026 In cancer research, failure can lead to an important discovery. That’s what happened when an international multicenter trial led by  MSK radiation oncologist and early drug development specialist Nancy Lee, MD , tried combining radiation and chemotherapy with an immunotherapy

Tumors with a biomarker called high microsatellite instability have been linked to inherited cancer mutations.

… Saturday, June 2, 2018 Summary MSK researchers have found that tumors with a particular genetic marker are likely to be associated with Lynch syndrome. Memorial Sloan Kettering researchers have found that the genetic condition Lynch syndrome may be associated with more cancers than earlier thought. Lynch

Leukemia patients may do better on CAR T cell therapy when they are treated early, before their disease relapses.

… Monday, April 3, 2017 Summary For patients with leukemia who relapse after chemotherapy, treatment options have traditionally been limited. At MSK, an experimental immunotherapy called CAR T therapy has expanded options for these patients. New research data presented at this year’s annual meeting of

Evidence from a recent study, led by MSK urologic surgeon, Behfar Ehdaie, MD, MPH, indicates that more patients with favorable Grade Group 2 prostate cancer can be successfully managed with active surveillance and achieve acceptable oncologic outcomes, even if later treatment is required.

… Friday, October 25, 2024 Growing evidence indicates that more patients with favorable Grade Group 2 prostate cancer can be successfully managed with active surveillance and achieve acceptable oncologic outcomes, even if later treatment is required. For the past five years, a team of MSK researchers has

Innovative imaging techniques shed light on intestinal damage that occurs after bone marrow transplant.

… Wednesday, July 17, 2019 VIDEO | 00:38 Mouse Intestinal Tissue This video of mouse intestinal tissue sheds light on graft-versus-host disease. The imaging technique shows clearly for the first time that after bone marrow transplantation the invading T cells from the donor (green) go mainly to the crypt

Meet Jaap-Jan “J. J.” Boelens, who joined MSK Kids in 2018 as Chief of the Stem Cell Transplantation and Cell Therapy Service.

… Monday, October 7, 2019 Jaap-Jan “J. J.” Boelens joined MSK Kids in 2018 as Chief of the Stem Cell Transplantation and Cell Therapy Service. Some of our MSK Kids patients asked him the questions they were most curious about. You’re a new doctor here at MSK Kids. Where did you come from? — James, 4 I

The combination immunotherapy of talimogene laherparepvec (T-VEC) and pembrolizumab met its primary endpoint of objective response rate at 24 weeks in our phase II clinical trial in patients with advanced sarcoma.

… Thursday, June 11, 2020 The combination immunotherapy of talimogene laherparepvec (T-VEC) and pembrolizumab met its primary endpoint of objective response rate at 24 weeks in our phase II clinical trial in patients with advanced sarcoma.  (1) The best objective response rate (ORR) was 30 percent (95%

MSK researchers developed an artificial intelligence system to detect cancer on digitized microscope slides.

… Monday, July 15, 2019 VIDEO | 00:45 Thomas Fuchs discusses how the computer model uses artificial intelligence to analyze digitized patient slides and detect cancer. Video Details Summary Cancer pathologists can spend hours each day studying slides that may yield little useful information. A type of

Memorial Sloan Kettering Cancer Center (MSK) announces its most recent awards and appointments for the institution’s physicians, scientists, nurses, and staff.

… Tuesday, March 16, 2021 Memorial Sloan Kettering Cancer Center (MSK) announces the following awards and appointments: Chrysothemis Brown Receives a 2021 Parker Institute for Cancer Immunotherapy Award Chrysothemis Brown Chrysothemis (Chryssie) Brown, MBBS, PhD , was recently awarded a 2021 Parker Institute